Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cholinergic Receptors: Muscarinic01:25

Cholinergic Receptors: Muscarinic

1.6K
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. 
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
1.6K
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

160
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
160
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.0K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.0K
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

5.5K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
5.5K
Cholinergic Receptors: Nicotinic01:15

Cholinergic Receptors: Nicotinic

2.0K
Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
2.0K
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

1.1K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel method for the identification and quantification of N6-methyladenosine motifs in RNA transcripts.

Molecular biology reports·2026
Same author

ToxMet: a web tool for toxicogenomic data analysis using genome-scale metabolic modeling.

Toxicological sciences : an official journal of the Society of Toxicology·2026
Same author

Geroprotection through modulation of heart rate variability, oxidative enzymes, tissue integrity, and gene expression by an Ayurvedic herbal formulation, Amalaki Rasayana.

Journal of Ayurveda and integrative medicine·2026
Same author

Cross-bridge model-based quantification of muscle metabolite alterations leading to fatigue during all-out knee extension exercise.

Frontiers in physiology·2026
Same author

Stent versus no stent in ureteroneocystostomy in live-related renal transplant: A randomized controlled trial.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia·2026
Same author

Behavioral attenuation of marble burying and digging mirrors evoked and non-evoked phenotypes in the endometriosis mouse model.

Scientific reports·2026

Related Experiment Video

Updated: May 16, 2025

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.3K

Developing muscarinic receptor M1 classification models utilizing transfer learning and generative AI techniques.

Souvik Dey1,2, Anders Wallqvist3, Mohamed Diwan M AbdulHameed4,5

  • 1Department of Defense Biotechnology High Performance Computing Software Applications Institute, Defense Health Agency Research and Development, Medical Research and Development Command, 504 Scott Street, Fort Detrick, MD, 21702-5012, USA.

Scientific Reports
|May 12, 2025
PubMed
Summary
This summary is machine-generated.

Machine learning models were developed to classify Muscarinic receptor subtype 1 (M1) interactions. These models effectively handle imbalanced data, improving drug discovery for neurological and respiratory diseases.

More Related Videos

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness
03:14

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness

Published on: December 6, 2024

466
Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice
07:09

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice

Published on: September 8, 2011

13.6K

Related Experiment Videos

Last Updated: May 16, 2025

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.3K
Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness
03:14

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness

Published on: December 6, 2024

466
Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice
07:09

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice

Published on: September 8, 2011

13.6K

Area of Science:

  • Pharmacology
  • Computational Chemistry
  • Machine Learning

Background:

  • Muscarinic receptor subtype 1 (M1) is a G protein-coupled receptor (GPCR) crucial for treating peripheral neuropathy, COPD, and cognitive disorders.
  • Identifying M1-interacting compounds is vital for rational drug design.
  • Publicly available bioactivity data is a valuable resource for drug discovery.

Purpose of the Study:

  • To develop machine learning-based classification models for the M1 receptor.
  • To address the challenge of imbalanced datasets common in bioactivity data.
  • To enhance the screening of chemical databases for potential M1-targeting drugs.

Main Methods:

  • Utilized publicly available bioactivity data for M1 receptor.
  • Investigated transfer learning strategies to improve model performance.
  • Employed generative models for oversampling the inactive compound class.
  • Developed M1 classification models using machine learning algorithms.

Main Results:

  • Successfully developed machine learning models for M1 receptor classification.
  • Demonstrated that transfer learning and generative oversampling reduce misclassification of inactive compounds.
  • Observed improved classification performance for M1 and other GPCR targets.
  • Validated the effectiveness of the developed models on imbalanced datasets.

Conclusions:

  • The developed M1 classification models enable rapid screening of large chemical libraries.
  • These models advance the rational drug design process for M1-related disorders.
  • The strategies employed are applicable to improving models for other GPCR targets.
  • This work facilitates efficient drug discovery for significant therapeutic areas.